The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Autoimmune Gastrointestinal Dysmotility Market Between 2026 And 2030?
The autoimmune gastrointestinal dysmotility market has experienced robust growth in recent years. It is projected to expand from $1.82 billion in 2025 to $1.92 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to increased autoimmune disease diagnoses, the prevalence of gastroparesis, the expansion of hospital gastroenterology, the use of immunosuppressive drugs, and heightened rare disease awareness.
The autoimmune gastrointestinal dysmotility market is projected to experience substantial growth over the coming years. Its valuation is forecast to reach $2.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.2%. This growth throughout the forecast period is primarily attributed to enhancements in early diagnostic capabilities, the introduction of personalized treatment methodologies, increasing demand for long-term care, the development of home-based nutrition therapy, and the expansion of autoimmune research efforts. Furthermore, key trends for this period include a heightened recognition of rare gastrointestinal disorders, an increase in the utilization of immunosuppressive treatments, the widening scope of nutritional and dietary management options, a rising adoption of multidisciplinary care approaches, and a significant focus on long-term symptom management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
What Influential Factors Are Boosting The Autoimmune Gastrointestinal Dysmotility Market Demand?
The expanding number of clinical trials is projected to fuel the advancement of the autoimmune gastrointestinal dysmotility market moving forward. Clinical trials are investigative studies designed to ascertain the safety, effectiveness, and best application of medical interventions, including pharmaceuticals, biologics, medical devices, and treatment protocols, in human participants, with the goal of expanding medical knowledge and enhancing patient care. The growth in clinical trials stems primarily from broadened regulatory frameworks that mandate trial registration, increased investment in pharmaceutical research and development, and the swift progression of innovation in novel therapeutic approaches such as immunotherapies and biologics that address autoimmune conditions impacting gastrointestinal motility. For autoimmune gastrointestinal dysmotility, these trials contribute to advancing treatment avenues by methodically assessing new immunosuppressive therapies, prokinetic agents, and biologics, identifying superior treatment regimens for managing gastrointestinal motility disorders, and establishing data-backed methodologies that facilitate regulatory approvals and the clinical adoption of breakthrough treatments targeting autoimmune-mediated gastrointestinal dysfunction. For instance, in November 2025, according to ClinicalTrials.gov, a US-based clinical trials registry managed by the National Institutes of Health, the total count of registered clinical studies reached 477,203 by the close of 2023 (encompassing 437,493 cumulative and 39,710 new registrations) and further increased to 520,877 by the end of 2024 (comprising 477,203 cumulative and 43,674 new registrations), marking a 9.1% year-on-year rise in overall registered studies. Consequently, the increasing volume of clinical trials is propelling the expansion of the autoimmune gastrointestinal dysmotility market.
What Segment Categories Are Evaluated In The Autoimmune Gastrointestinal Dysmotility Market Study?
The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs)
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Who Are The Firms Contributing To The Autoimmune Gastrointestinal Dysmotility Market Ecosystem?
Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
Access The Complete Autoimmune Gastrointestinal Dysmotility Market Report:
Which Region Holds The Largest Share In The Autoimmune Gastrointestinal Dysmotility Market?
North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2025. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Autoimmune Gastrointestinal Dysmotility Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24160&type=smp
Browse Through More Reports Similar to the Global Autoimmune Gastrointestinal Dysmotility Market 2026, By The Business Research Company
Autoimmune Disease Diagnosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Autoimmune Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Veterinary Autoimmune Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model